You are here

Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Medizinische Hochschule Hannover
Hannover, , 30625 Germany
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must be at least 18 years of age at study index;

- Patients must have a diagnosis of PAH. PAH is conventionally defined as a mean
pulmonary arterial pressure (PAP) of > 25 mmHg and a pulmonary capillary wedge
pressure (PCWP) ≤ 15 mmHg and a pulmonary vascular resistance (PVR) ≥ 240 dynes/s/cm-5
at right heart catheterization;

- Patients must have initiated sildenafil for the treatment of their PAH; at dose ≥ 20
mg tid within 5 years prior to study initiation

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patient has known contraindications to sildenafil at study index;

- Patient participated in an investigational study of sildenafil treatment for PAH
during the period beginning 6 months prior to study index

NCT01365585
Pfizer
Completed
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pulmonary Arterial Hypertension
NCT02060487
All Genders
18+
Years
Multiple Sites
Pulmonary Arterial Hypertension
NCT03364244
All Genders
0+
Years
Tokyo,

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now